Literature DB >> 26569549

Reprint of "Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)".

Luiza Reali Nazario1, Régis Junior Antonioli1, Katiucia Marques Capiotti1, Jaime Eduardo Cecílio Hallak2, Antonio Waldo Zuardi2, José Alexandre S Crippa2, Carla Denise Bonan3, Rosane Souza da Silva4.   

Abstract

Cannabidiol (CBD) has been investigated in a wide spectrum of clinical approaches due to its psychopharmacological properties. CBD has low affinity for cannabinoid neuroreceptors and agonistic properties to 5-HT receptors. An interaction between cannabinoid and purinergic receptor systems has been proposed. The purpose of this study is to evaluate CBD properties on memory behavioral and locomotor parameters and the effects of pre-treatment of adenosine receptor blockers on CBD impacts on memory using adult zebrafish. CBD (0.1, 0.5, 5, and 10mg/kg) was tested in the avoidance inhibitory paradigm and anxiety task. We analyzed the effect of a long-term caffeine pre-treatment (~20mg/L - four months). Also, acute block of adenosine receptors was performed in co-administration with CBD exposure in the memory assessment. CBD promoted an inverted U-shaped dose-response curve in the anxiety task; in the memory assessment, CBD in the dose of 5mg/Kg promoted the strongest effects without interfering with social and aggressive behavior. Caffeine treatment was able to prevent CBD (5mg/kg) effects on memory when CBD was given after the training session. CBD effects on memory were partially prevented by co-treatment with a specific A2A adenosine receptor antagonist when given prior to or after the training session, while CBD effects after the training session were fully prevented by adenosine A1 receptor antagonist. These results indicated that zebrafish have responses to CBD anxiolytic properties that are comparable to other animal models, and high doses changed memory retention in a way dependent on adenosine.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Adenosine; Anxiety; Caffeine; Cannabidiol; Memory; Zebrafish

Mesh:

Year:  2015        PMID: 26569549     DOI: 10.1016/j.pbb.2015.11.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Cannabidiol improves Nile tilapia cichlid fish welfare.

Authors:  Bruno Camargo-Dos-Santos; Marina Sanson Bellot; Isabela Inforzato Guermandi; João Favero-Neto; Maira da Silva Rodrigues; Daniel Fernandes da Costa; Rafael Henrique Nóbrega; Renato Filev; Eliane Gonçalves-de-Freitas; Percília Cardoso Giaquinto
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

2.  Developmental Effects of Cannabidiol and Δ9-Tetrahydrocannabinol in Zebrafish.

Authors:  Dennis R Carty; Cammi Thornton; James H Gledhill; Kristine L Willett
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

3.  Multigenerational consequences of early-life cannabinoid exposure in zebrafish.

Authors:  Dennis R Carty; Zachary S Miller; Cammi Thornton; Zacharias Pandelides; Marisa L Kutchma; Kristine L Willett
Journal:  Toxicol Appl Pharmacol       Date:  2018-12-27       Impact factor: 4.219

4.  Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.

Authors:  Antonio W Zuardi; Natália P Rodrigues; Angélica L Silva; Sandra A Bernardo; Jaime E C Hallak; Francisco S Guimarães; José A S Crippa
Journal:  Front Pharmacol       Date:  2017-05-11       Impact factor: 5.810

5.  Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.

Authors:  Ila M Linares; Antonio W Zuardi; Luis C Pereira; Regina H Queiroz; Raphael Mechoulam; Francisco S Guimarães; José A Crippa
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

Review 6.  The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.

Authors:  Mashal Ahmed; Isabelle Boileau; Bernard Le Foll; Andre F Carvalho; Stefan Kloiber
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.